Enrique Koh, MD
Family Medicine · Ebensburg, PANPI 1184629552
Payments from drug & device makers
Across 313 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$576
- Novo Nordisk$487
- GSK$465
- AstraZeneca$347
- Lilly USA, LLC$347
- Amgen$282
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,86499%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 44 | $576 |
| Novo Nordisk | 33 | $487 |
| GSK | 29 | $465 |
| AstraZeneca | 18 | $347 |
| Lilly USA, LLC | 26 | $347 |
| Amgen(2 entities) | 19 | $282 |
| Boehringer Ingelheim | 18 | $271 |
| E.r. Squibb & Sons, L.L.C. | 8 | $239 |
| Merck | 17 | $230 |
| AbbVie | 11 | $187 |
| Amarin Pharma, Inc. | 10 | $152 |
| Exact Sciences | 6 | $138 |
| Johnson & Johnson | 8 | $127 |
| Kowa Pharmaceuticals America, Inc. | 8 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $106 |
| Novartis | 6 | $93 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $90 |
| Dexcom, Inc. | 5 | $78 |
| Astellas Pharma US Inc | 6 | $73 |
| Sanofi-aventis U.S. LLC | 5 | $70 |
| Irhythm Technologies, Inc. | 2 | $51 |
| Abbott | 3 | $50 |
| Phathom Pharmaceuticals, Inc. | 2 | $40 |
| Bayer | 2 | $35 |
| Shire North American Group Inc | 2 | $29 |
| Ardelyx, Inc. | 1 | $28 |
| Stryker | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Sobi, Inc | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Circassia Inc. | 1 | $14 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Dynavax Technologies Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$125
- TRELEGY ELLIPTA$112
How this compares
$4,900 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 126 | $126,796 |
| TrulicityDulaglutide | 107 | $118,803 |
| JardianceEmpagliflozin | 88 | $86,061 |
| RybelsusSemaglutide | 28 | $55,981 |
| FarxigaDapagliflozin Propanediol | 38 | $42,577 |
| TradjentaLinagliptin | 43 | $42,384 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $40,425 |
| Repatha SureclickEvolocumab | 59 | $36,150 |
| OzempicSemaglutide | 33 | $35,270 |
| MounjaroTirzepatide | 26 | $33,815 |
| XareltoRivaroxaban | 35 | $22,274 |
| MyrbetriqMirabegron | 31 | $20,914 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $17,275 |
| JanuviaSitagliptin Phosphate | 20 | $16,564 |
| VascepaIcosapent Ethyl | 12 | $11,790 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $347 | $152,618133 claims |
| Boehringer IngelheimJardiance, Tradjenta | $271 | $128,445131 claims |
| PfizerEliquis | $576 | $126,796126 claims |
| Novo NordiskRybelsus, Ozempic | $487 | $91,25061 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $465 | $64,61194 claims |
| AstraZenecaFarxiga | $347 | $42,57738 claims |
| Johnson & JohnsonXarelto | $127 | $22,27435 claims |
| Astellas Pharma US IncMyrbetriq | $73 | $20,91431 claims |
| MerckJanuvia | $230 | $16,56420 claims |
| AbbVieLinzess, Synthroid | $187 | $10,32774 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Ebensburg
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.